NCT01614431

N Acetyl Cysteine for Cystinosis Patients

N Acetyl Cysteine Can Decrease the Progression of Renal Disease in Cystinosis Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 1 Year – 18 Years
• Healthy volunteers: Not accepted

Summary

This study intends to verify the interference of N acetyl cysteine in the progression of chronic kidney disease in patients with Nephropathic Cystinosis.

Detailed description

Patients with Nephropathic Cystinosis have an increased oxidative stress and go to end-stage renal disease, even when all steps of the treatment are done. Therefore, this study is conducted to verify the interference of the stress oxidative in the progression of the renal disease with the use of an oxidant drug, N acetyl cysteine (NAC). The investigators selected patients with good compliance of the treatment. In these patients the investigators evaluate the serum creatinine, creatinine clearance estimated by Schwartz Formula, cystatin C and a marker of oxidative stress, TBARS ( thiobarbituric acid substances). The variables are analyzed 6 months before the introduction of NAC and the three months after NAC.

Conditions

• Renal Disease
• Cystinosis

Interventions

Type	Name	Description
DRUG	N acetyl cysteine	N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
DRUG	N acetyl cysteine	N acetyl cysteine for cystinosis patients CKD stages 1 to 4

Timeline

• Start date: 2011-03-01
• Primary completion: 2012-01-01
• Completion: 2012-05-01
• First posted: 2012-06-08
• Last updated: 2012-06-20